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Monocyte recruitment to inﬂamed arterial endothelium initiates
plaque formation and drives progression of atherosclerosis. Three
distinct monocyte subsets are detected in circulation (CD14++CD16−,
CD14++CD16+, and CD14+CD16++), and each may play distinct roles
during atherogenesis and myocardial infarction. We studied a range
of subjects that included otherwise healthy patients with elevated
serum triglyceride levels to patients presenting with acute myocar-
dial infarction. Our objective was to correlate an individual’s risk
with the activation state of each monocyte subset as a function
of changes in adhesion receptor expression using ﬂow cytometric
quantitation of integrins and L-selectin membrane expression. A
microﬂuidic-based laboratory-on-a-chip was developed to quantify
the adhesion efﬁciency of monocytes sheared in whole blood on
vascular cell adhesion molecule-1, while characterizing adhesion
receptor expression and topography on captured monocytes.
CD14++CD16+ monocytes adhered with sevenfold higher efﬁ-
ciency than other subsets, and in patients with myocardial infarc-
tion the capture efﬁciency of this subset was double that for
healthy subjects. In patients with hypertriglyceridemia, this increase
in monocyte adhesion was attributable to CD14++CD16+ uptake of
triglyceride-rich lipoproteins and subsequent signaling via a Phos-
pholipase C–dependent mechanism to increase CD11c expression,
very late antigen–4 function, and integrin coclustering within focal
adhesive sites on vascular cell adhesion molecule-1. In summary,
we introduce a unique laboratory-on-a-chip method for quantify-
ing the activation state of monocyte subsets. These experiments
reveal that CD11c/CD18 is an inducible integrin whose expression
correlates with a monocyte inﬂammatory state in subjects at risk
for atherogenesis and in patients with myocardial infarction.
B2-integrin | cell arrest | shear ﬂow
Monocyte activation and adhesion to inﬂamed endotheliumis an obligate step in the initiation of atherosclerosis (1).
Despite the accepted paradigm of atherosclerosis as an inﬂam-
matory disease, population-wide studies that correlate established
biomarkers (e.g., monocyte chemoattractant protein–1, myelo-
peroxidase, c-reactive protein) with the progression of coronary
artery disease (CAD) and during acute myocardial infarction (MI)
fail to provide a personalized quantitative measure of activation
at the level of the participating immune cells (2). Monocyte re-
cruitment to sites of atherogenesis is associated with accumulation
of lipoproteins and differentiation of monocytes into foamy mac-
rophages, but the exact mechanisms through which circulating
lipoproteins interact with blood monocytes remain unclear. Al-
though low-density lipoprotein (LDL) is a clinically important
marker used to predict onset of CAD, serum triglyceride level and
its content in triglyceride-rich lipoproteins (TGRLs) are emerging
as metabolically driven biomarkers for predicting acute cardio-
vascular events (3). In this context, TGRLs containing apolipo-
protein C-III remain in circulation due to diminished hepatic
clearance (4), are readily taken up by monocytes in blood (5), and
are endocytosed by endothelial cells, resulting in vascular cell
adhesion molecule-1 (VCAM-1) up-regulation and enhanced re-
cruitment of monocytes in shear ﬂow (6). Activation of monocytes
and their increased inﬂux to coronary arteries correlate with
plaque progression and instability, and inﬂammatory monocytes
contribute to infarct size (7).
Monocytes in the circulation represent a heterogeneous pop-
ulation, from naïve myeloid progenitors in the bone marrow to
differentiated subsets that are stimulated during transport
through microvasculature of the spleen and adipose tissue (8).
Three major subsets of monocytes have been identiﬁed based on
relative expression of the lipopolysaccharide coreceptor CD14 and
the FcγRIII receptor CD16 (9). The “classical”monocyte (CD14++
CD16−, Mon1) accounts for 80–90% of cells in circulation,
whereas the “intermediate” (CD14++CD16+, Mon2) and “non-
classical” (CD14+CD16++, Mon3) subsets account for the re-
maining 10–20%. The relative distribution of monocytes observed
in the circulation is dynamic and changes as a function of the in-
ﬂammatory and metabolic drivers that inﬂuence differentiation
between the subsets and as a function of the extent of CAD. For
example, Mon2 and Mon3 are more prevalent in subjects with
elevated triglycerides and are reported as proinﬂammatory cyto-
kine-producing subsets whose numbers are elevated in the circu-
lation of patients with atherosclerosis and CAD (10). Changes in
expression of integrins [CD11b, very late antigen–4 (VLA-4)] and
L-selectin provide a gross measure of monocyte inﬂammatory
activation in blood, but these methods do not gauge the relative
level of monocyte activation from resting to maximally activated
and poised for recruitment to inﬂamed arteries.
Functional studies of monocyte recruitment indicate that
Mon2 has high potential to participate in atherosclerosis based
on differential expression of chemokine and adhesion receptors
that orchestrate their recruitment to vasculature with ele-
vated VCAM-1 expression and interstitial MCP-1 (11). We
have identiﬁed CD11c/CD18 as a functional receptor expressed
on an inﬂammatory subset of monocytes (5). CD11c/CD18 is up-
regulated in apolipoprotein E–deﬁcient mice made dyslipidemic
on a high-fat diet, and genetic depletion of CD11c abrogated the
development of atherosclerosis (12). CD11c/CD18 and CD49d/
CD29 (VLA-4) were identiﬁed as the principal receptors neces-
sary for facilitating monocyte arrest on VCAM-1 (12). In humans
with hypertriglyceridemia, expression of CD11c is up-regulated
on circulating monocytes within hours of consumption of a high-
fat meal (5). This up-regulation of CD11c correlated with the
uptake of TGRL, appearance of foam cells in blood, and en-
hanced efﬁciency of monocytes to recruit to VCAM-1 in shear
ﬂow. In vitro studies conﬁrmed that uptake of TGRLs by mono-
cytes in blood is mediated by LDL receptor–1 (LRP-1) (5),
however the mechanism linking hypertriglyceridemia to CD11c
up-regulation and increased VLA-4 function remains unclear.
These ﬁndings prompted our current focus on the mechanism
by which up-regulation of CD11c expression during hyper-
triglyceridemia and cardiovascular disease is related to the
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increased capacity of monocytes to activate VLA-4 and recruit
on VCAM-1.
Although previous studies have suggested an important role
for Mon2 and CD11c in atherosclerotic cardiovascular disease,
no prior study has integrated phenotypic characterization of
monocyte subsets with a functional readout of cell activation
state. We developed a microﬂuidic-based laboratory-on-a-chip
assay that facilitates interrogation of monocytes capturing on
VCAM-1 under ﬂuid shear stress to mimic exposure to focal sites
of arterial inﬂammation. Through these experiments, we show
that Mon2 uptake of TGRL via LRP-1 leads to increased CD11c
expression and VLA-4 function via a Phospholipase C (PLC)-
dependent mechanism that involves integrin activation and
colocalization within focal adhesive sites on VCAM-1. Co-
operative regulation of Mon2 integrin function makes these cells
a dynamic population that responds to perturbations in lipid
uptake (among patients with high triglycerides) and local in-
ﬂammation at the level of the coronary plaque (in MI).
Results
CD11c on Inﬂammatory Monocytes Along with Serum Triglycerides
Are Elevated in the Postprandial State. Monocyte adhesion re-
ceptor expression is rapidly regulated in response to uptake of
TGRL, thereby facilitating recruitment to inﬂamed aortic en-
dothelium during hypercholesterolemia-driven atherogenesis (5,
12). This observation motivated the measurement of acute changes
in expression of integrins CD11b/CD18, CD11c/CD18, and
CD49d/CD29 (VLA-4), as well as CD62L (L-selectin) on mono-
cyte subsets to detect their activation state in blood samples from
subjects during the fasting (Fig. S1) and postprandial state (Fig. 1).
In response to a high-fat meal, CD11c expression increased by
60% on Mon2, whereas expression of other adhesion receptors did
not change signiﬁcantly on Mon2 or other subsets (Fig. 1A). We
next assessed whether a subject’s fasting triglyceride (fTG) level
was correlated with the extent of CD11c up-regulation on
monocyte subsets. There was a trend for increased CD11c with
triglyceride that reached signiﬁcance at levels above 200 mg/dL
only on Mon2, whereas CD11c expression on the other subsets
did not change postprandial (linear regression of CD11c on
Mon2 over range of fTG; Pearson r = 0.7563, P < 0.0001) (Fig.
1B). These data suggest that up-regulation of CD11c on Mon2
is associated with increased baseline cardiovascular risk in
hypertriglyceridemic subjects.
CD11c Up-Regulation Tracks in Time with Triglyceride Levels on Mon2
in High-Risk Subjects. Increased fructose consumption raises a
subject’s serum triglyceride levels signiﬁcantly following a 2-wk
fructose-supplemented diet (13). We evaluated changes in CD11c
expression on circulating monocytes from subjects participating in
a 2-wk high-fructose diet and tracked CD11c levels with serum
triglyceride concentration over a 24 h feeding study (Fig. 2).
Subjects were categorized into low- or high-risk groups based on
fTG levels, and CD11c expression was measured on blood
monocytes at intervals throughout the day. Among high-risk
subjects, Mon2 exhibited a steady increase in expression of
CD11c rising 100% above fasting levels, whereas no signiﬁcant
change in CD11c was observed on the other monocyte subsets or
on those from low-risk subjects (Fig. 2A). Triglycerides increased
threefold more for high-risk versus low-risk subjects (Fig. 2B).
The change in CD11c on Mon2 tracked closely in time with the
rise and fall in triglyceride concentration for high-risk subjects
over 24 h, suggesting that these monocytes respond to acute
changes in metabolic state.
CD11c Expression on Mon2 Correlates with Biomarkers of MI Severity.
Monocytes are the principal inﬂammatory cells that initiate and
participate in arterial plaque progression and instability, which
motivated measurement of acute changes in adhesion molecule
expression to quantify a monocyte activation state in blood.
Receptor expression of CD11c and VLA-4 was ∼twofold higher
on Mon1 and Mon2 from MI patients compared with those of
fasting subjects in the feeding study, whereas there was no sig-
niﬁcant difference in adhesion molecule expression on Mon3
(Fig. 3A). Mon1 from MI patients had increased expression of
CD62L compared with fasting subjects, and because MI patients
have on average twice as many circulating Mon1 compared with
healthy subjects (14), these data suggest mobilization of inacti-
vated monocytes into the circulation in response to MI. To
evaluate the relationship between CD11c expression and the
severity of MI, we assessed the number of CD11c receptors on
monocytes versus circulating levels of creatine kinase (Fig. 3B)
(Pearson r = 0.6298, R2 = 0.39, P = 0.005) and troponin levels
(Fig. 3C) (Pearson r = 0.6919, R2 = 0.48, P = 0.002), each of
which is associated with myocardial infarct size. CD11c receptor
number on Mon2 positively correlated with peak levels of both
troponin and creatine kinase, whereas no signiﬁcant correlation
was observed for Mon1 or Mon3 subsets. We also evaluated the
relationship between culprit artery plaque characteristics as im-
aged by intravascular virtual histology, rendered from the ultra-
sound-derived echogenic properties of the obstructed coronary
artery. MI patients were segregated based on necrotic plaque
volume and compared for receptor expression of CD11c on their
blood monocytes (Fig. 3D). Patients with a necrotic plaque vol-
ume ≥25% registered a signiﬁcantly greater CD11c receptor
number only on Mon2 and not other monocyte subsets. These
data reveal that CD11c is elevated on Mon2 in MI patients
compared with high-risk healthy subjects and that it increases in
proportion with elevated clinical correlates of MI severity.
CD11c Expression and VLA-4 Afﬁnity Are Increased on Mon2 Following
TGRL Uptake in a PLC-Dependent Manner. We have previously
reported that TGRL uptake is mediated through LRP-1 and
blocked with the LRP-1 antagonist receptor-associated protein
(RAP). To elucidate the mechanism through which hyper-
triglyceridemia leads to increased CD11c expression on mono-
cytes, side scatter (SSC) proﬁle and CD11c expression were
measured by FACS on freshly isolated monocytes incubated with
TGRL isolated from postprandial blood of ﬁve subjects fed
a high-fat meal. Mon1 and Mon2 exhibited a signiﬁcant 30%
increase in SSC following incubation with TGRL, and this cor-
related with uptake of apolipoprotein particles and formation of
lipid droplets. To conﬁrm the speciﬁcity of lipid endocytosis, we
pretreated monocytes with RAP, which blocked lipid uptake by
54% for Mon1 and 100% for Mon2 (Fig. S2 B and C). Concom-
itant with lipid uptake, we observed a 70% increase in CD11c
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Fig. 1. Adhesion receptor expression on monocyte subsets in a fasting and
postprandial state. (A) Receptor expression on monocyte subsets as labeled
in postprandial subjects 3.5 h after consumption of a high-fat meal. Data are
expressed as the percent change in receptor expression relative to fasting
state. Signiﬁcance was determined using a one-way ANOVA with a Tukey
posttest, *P < 0.05, ***P < 0.005. (B) CD11c receptor expression on Mon2
versus Mon1 and Mon3 plotted as a function of fTGs. Subjects were cate-
gorized into low-risk (n = 15) or high-risk (n = 11) groups based on fTGs and
postprandial change in CD11c. Subjects with fTGs ≥200 mg/dL were grouped
as high risk (right of horizontal dashed line). Data are representative of 26
subjects (10 female). Signiﬁcant changes in CD11c expression were de-
termined using a repeated measures ANOVA with Dunnets posttest, ***P <
0.005, ****P < 0.001. Signiﬁcance comparing Mon2 to other monocytes was
determined using a one-way ANOVA with a Tukey posttest.
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expression on Mon2, a level equivalent to that measured ex vivo in
postprandial blood. Integrin up-regulation was also inhibited down
to baseline levels with RAP (Fig. S2 A and B) pretreatment (Fig.
4A). There was no signiﬁcant change in CD11c expression on
Mon1 or Mon3 (Fig. 4B).
Because ligation of LRP-1 triggers PLC activation, which leads
to a rise in intracellular Ca2+, activation of PKC, and subsequent
degranulation (15, 16), we hypothesized that CD11c up-regula-
tion following TGRL uptake is dependent on this signaling
pathway. To test this hypothesis, we pretreated monocytes with
the PLC inhibitor U73122 and measured lipid uptake and CD11c
expression. PLC inhibition did not reduce the capacity of Mon2
to endocytose TGRL but did prevent CD11c up-regulation in the
presence of TGRL; these effects reveal a speciﬁc pathway, as they
were not observed in response to stimulation with MCP-1 (Fig.
4A, Fig. S2B). To assess Mon2 sensitivity to the triglyceride con-
tent of the TGRL, we plotted the extent of CD11c up-regulation
against triglyceride concentration, which yielded a tight correla-
tion (Pearson r = 0.9767, R2 = 0.9539, P = 0.004) (Fig. 4B). In
contrast, Mon1 and Mon3 showed no signiﬁcant increase in
CD11c with triglyceride content (Pearson r = 0.8435, R2 = 0.7144,
P = 0.07).
To quantify changes in VLA-4 function in response to up-
take of TGRL and inside-out signaling, or allosteric activation
by addition of Mn2+, we used 4-[(N′-2-methylphenyl)ureido]-
phenylacetyl-L-leucyl-L-α-aspartyl-L-valyl-L-prolyl-L-alanyl-L-
alanyl-L-lysine - FITC (LDV-FITC) as a reporter of conversion
of the integrin to the high-afﬁnity conformation. Mon2
exhibited the highest expression of LDV-FITC at baseline
compared with Mon1 and Mon3 (Fig. S2 D and E), and fol-
lowing uptake of TGRL or activation via Mn2+ doubled its
expression. Signaling via TGRL uptake was blocked by pre-
treatment with RAP or the PLC inhibitor U73122, whereas
extracellular activation via Mn2+ was unaffected (Fig. 4A).
Lab-on-a-Chip Phenotyping of Monocytes Recruited on VCAM-1 Under
Shear Flow. Monocyte recruitment from the blood stream to
a nascent site of arterial plaque formation expressing VCAM-1 is
an early step in atherogenesis (1). Our strategy was to charac-
terize the integrin dependence of monocyte recruitment using
a custom laboratory-on-a-chip microﬂuidic channel that reca-
pitulates arterial hydrodynamic transport (Fig. 5A) (17). Whole
blood was sheared over a glass coverslip functionalized with
recombinant VCAM-1, and arrested monocyte subsets were dis-
criminated based on the relative immunoﬂuorescence of anti-
bodies to CD14 and CD16 (Fig. 5B and Fig. S3). Mon2 exhibited
a sevenfold greater propensity to arrest on VCAM-1 compared
with the other subsets (Fig. 5C). Discrimination of Mon2 in this
assay is highlighted by the absence of a signiﬁcant difference in
the percent of Mon1, Mon3, or neutrophils (∼0.05%) recruited
from blood samples of MI patients versus low- and high-risk
subjects. In contrast, Mon2 from MI patients exhibited twice the
capacity to capture under shear stress than monocytes from low-
risk subjects. Moreover, a smaller albeit signiﬁcant increase in
Mon2 recruitment was detected in the high- versus low-risk
subjects (Fig. 5C). Thus, adhesion of Mon2 exhibited a hierarchy
in recruitment capacity among subjects with increased trigly-
cerides and in response to acute MI, whereas Mon1 and Mon3
did not. Plotting recruitment capacity as a function of CD11c
expression on Mon2 revealed a linear correlation (Pearson r =
0.5649, R2 = 0.3191, P = 0.006) between CD11c receptor number
and Mon2 recruitment that discriminated the different patient
populations (Fig. 5D).
CD11c and VLA-4 cooperate in mediating arrest of mono-
cytes on VCAM-1 in response to postprandial elevation of tri-
glycerides and during atherogenesis (5, 12). We evaluated the
integrin speciﬁcity during arrest by addition of function-blocking
antibodies before shearing blood over a VCAM-1 substrate.
Pretreatment of blood samples with antibody 496K, which binds
to an allosteric site on the metal-ion–dependent adhesion site
(MIDAS) domain and inactivates high-afﬁnity CD11c binding
function (18), reduced the arrest fraction of Mon2 for high-risk
and MI subjects to levels equivalent to that of low-risk subjects
(Fig. 5E). Inactivation of CD11c did not further diminish the
already low recruitment efﬁciency of Mon1 and Mon3 (Fig. S4 A
and B). In contrast, treatment of blood with function-blocking
antibody to VLA-4 abrogated monocyte arrest on VCAM-1 that
was equivalent to blocking with anti-VCAM-1 (Fig. S4C). These
data conﬁrm that Mon2 adhesion on VCAM-1 in shear is
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Fig. 2. Kinetics of CD11c expression on monocyte subsets tracked with se-
rum triglyceride over a 24 h feeding study. (A) Monocyte CD11c expression
and serum triglyceride levels plotted versus time for low-risk subjects (fTG
<200 mg/dL, n = 4). (B) Monocyte CD11c expression and serum triglyceride
levels plotted versus time for high-risk subjects (fTG >200 mg/dL, n = 5).
Three meals were administered at 9:00 AM, 1:00 PM, and 6:00 PM, as in-
dicated by black arrows. The percent change in CD11c expression from
fasting was calculated at 1:00 PM, 3:00 PM, 6:00 PM, 12:00 AM, and 8:00 AM
(the following day). Statistics were measured against fasting values, and
signiﬁcance was determined using a repeated measures ANOVA with Dun-
nets posttest, *P < 0.05, **P < 0.01, ***P < 0.005.
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a cooperative process partly dependent on the conformation of
CD11c, but predominantly dependent on VLA-4.
Monocyte Capture on VCAM-1 Is Regulated by Activation of CD11c
and VLA-4. To characterize the integrin binding mechanisms un-
derlying the hierarchy in Mon2 recruitment efﬁciency observed
between postprandial subjects and MI patients, we used total
internal reﬂection ﬂuorescence (TIRF) microscopy, which pro-
vides optical discrimination of receptor enrichment within the
plane of adhesive contact with VCAM-1. Blood samples obtained
from meal study subjects and MI patients were sheared across
a substrate of VCAM-1 in the microﬂuidic ﬂow channels, and
integrin receptor interactions were imaged on adherent mon-
ocytes after labeling with ﬂuorescent antibodies against CD11c
or VLA-4 (Fig. 6A). CD11c receptor number increased three-
fold within the contact region for high- versus low-risk subjects,
and this was augmented by 25% in samples from MI patients
(Fig. 6A).
To determine whether CD11c afﬁnity state inﬂuences integrin
binding to VCAM-1 and the efﬁciency of monocyte recruitment
in shear, blood was pretreated with allosteric antibodies that
stabilize the inactivated (496K) and activated (496B) ligand-
binding conformation of CD11c (18). Fresh blood obtained from
fasting subjects was treated with allosteric or isotype control
antibody and subsequently sheared on VCAM-1 and compared
for VLA-4 receptor number and focal clustering on captured
monocytes (Fig. 6B). Allosteric activation elicited a ∼onefold
enrichment in CD11c number in contact with VCAM-1, and this
translated to a concomitant increase in VLA-4, which rose to a
level equivalent to that supporting recruitment of Mon2 from the
MI subject’s blood (Fig. 6 A and B). In contrast, stabilizing
CD11c in an inactive state signiﬁcantly diminished integrin ac-
cumulation to levels below the detection limit of ∼100 sites/μm2
as assessed by labeling with isotype control antibody. This was
accompanied by a diminished capacity for both integrins to or-
ganize into focal clusters on VCAM-1.
To determine the mechanism underlying increased CD11c and
VLA-4 expression and clustering at the contact site, we assessed
the topography of CD11c and VLA-4 on monocytes activated by
uptake of TGRL. Two-color TIRF images revealed that treat-
ment with TGRL, and not a control emulsion (intralipid), eli-
cited a doubling in the number of VLA-4 colocalized with CD11c
on arrested monocytes (Fig. 6C). In contrast, CD45 receptor
topography remained unaltered in response to TGRL, conﬁrm-
ing speciﬁcity in the synergistic redistribution of CD11c and
VLA-4 within focal clusters. To gauge the importance of sig-
naling via PLC, monocytes were treated with TGRL along with
the inhibitor U73122. A decrease in the coalescence of VLA-4
with CD11c to baseline was observed. Taken together, these data
indicate that CD11c numbers exceed that of VLA-4 within the
contact region and that the organization and activation state of
CD11c within sites of focal adhesion is synergistic with VLA-4 in
mediating ﬁrm arrest of monocytes on VCAM-1.
Discussion
Inﬂammatory monocytes in the circulation precipitate athero-
sclerosis and are associated with the onset of MI, yet functional
biomarkers that reliably predict their participation in disease ini-
tiation and progression are lacking (19). By interrogating mono-
cyte receptor number and adhesion function in blood samples
soon after venipuncture or cardiac catheterization, we identiﬁed
CD11c on Mon2 as a reliable biomarker that increased with the
extent of a subject’s hypertriglyceridemia and in proportion to the
severity of myocardial injury in MI patients. After shearing blood
across a VCAM-1 substrate in a unique microﬂuidic device, we
observed (i) a ∼sevenfold higher recruitment efﬁciency for Mon2
over Mon1 or Mon3, (ii) a hierarchy in capture efﬁciency that was
∼50% higher for MI patients than for postprandial hyper-
triglyceridemic subjects at high risk of cardiovascular disease
(CVD), (iii) that CD11c mediates Mon2-speciﬁc adhesion efﬁ-
ciency and is up-regulated via LRP-1–mediated uptake of TGRL
and signaling through PLC, and (iv) that CD11c activation state
regulates the number of VLA-4 enrichment with the contact re-
gion that supports shear-resistant monocyte capture on VCAM-1.
Acute Changes in Monocyte Phenotype Correlate with Dyslipidemia
and Atherosclerosis. CD11c expression and function increase on
monocytes in the blood of humans and mice that take up very-
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Fig. 4. TGRL uptake increases membrane CD11c and VLA-4 afﬁnity on
Mon2. (A) CD11c expression (left axis, solid colors) and LDV-FITC expression
(right axis, checkered boxes) on Mon2 following incubation with post-
prandial TGRL. Signiﬁcance for TGRL alone, MCP-1 (30 nM), or Mn2+ (1 mM)
treated monocytes was compared versus control (open white box). Blocking
with RAP or PLC was compared against TGRL alone. Signiﬁcance was de-
termined by one-way ANOVA with Tukey posttest, *P < 0.05, **P < 0.01. (B)
Percent change from baseline levels of CD11c receptor expression on Mon2
and all other monocytes plotted as a function of the mean triglyceride
concentration of TGRL particles incubated with monocytes.
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Fig. 5. Lab-on-a-chip analysis of monocyte recruitment on VCAM-1 under
hydrodynamic shear. (A) Schematic and image of the arterial mimetic device
detailed in SI Materials and Methods. (B) Arrested monocytes identiﬁed by
anti-CD14 (red) and anti-CD16 (green) acquired using wide-ﬁeld immuno-
ﬂuorescence (images are representative of 150–200 monocytes phenotyped
per subject). (Scale bar, 10 μm.) (C) Postprandial monocyte recruitment ef-
ﬁciency for subjects categorized as low (fTG <200 mg/dL, n = 8) and high risk
(fTG >200 mg/dL, n = 5) and MI patients (n = 8). (D) Recruitment efﬁciency
plotted as a function of CD11c expression for postprandial study subjects and
MI patients. A regression curve was ﬁt to the means of low-risk, high-risk,
and MI groups (Pearson r = 0.9957, R2 = 0.9915, P = 0.0587) (E) Integrin
speciﬁcity of monocyte recruitment studied by application of blocking
antibodies against CD11c and VLA-4 depicted for Mon2 and other subsets
(Fig. S4). Statistics were measured against samples treated with the isotype
antibody control for each group, and signiﬁcance was determined by one-
way ANOVA with Tukey posttest, **P < 0.01, ***P < 0.005.
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low-density lipoprotein (vLDL) particles in vitro (5, 12). Here we
report that CD11c expression on Mon2 in postprandial blood
samples was up-regulated up to threefold more than conven-
tional measures of acute monocyte activation, including increases
in CD11b, CD49d, and shedding of CD62L. CD11c expression
level also discriminated low- versus high-risk subjects based on
fTGs of these individuals. Analysis of Mon2 in the high-fructose
feeding study conﬁrmed that this subset, and not monocytes in
general, provides a dynamic measure of systemic metabolic stress
among high-risk subjects. We also conﬁrmed in an in vitro assay
that incubating monocytes with TGRLs elicited an increase in
membrane CD11c at levels equivalent to that measured in
hypertriglyceridemic subjects ex vivo. LRP-1–mediated uptake
and integrin up-regulation were dependent on PLC, as both VLA-
4 conversion to high afﬁnity and adhesion to VCAM-1 increased
with TGRL uptake. Whether monocyte activation reﬂects
changes in a single population induced in the circulation, or
a change in lineage dynamics during chronic inﬂammation,
requires further investigation.
Discrimination of a Mon2 Activation State in Blood Samples of High-
Risk and MI Patients. Inﬂammatory monocytes are an independent
risk factor for CAD even after adjusting for other confounding
conditions such as diabetes, hypertension, and hyperlipidemia
(20). Direct evidence that inﬂammatory monocytes contribute to
CVD derives from monocyte subset immunophenotyping, which
has shown that inﬂammatory monocytes express CCR2, CX3CR1,
and CCR5; up-regulate CD11b receptor expression; and bind
VCAM-1 (21). Our studies of adhesion receptor changes on
postprandial monocytes and on those fromMI patients conﬁrmed
the trend for CD11b up-regulation, but changes in CD11c ex-
pression and adhesion function correlated more closely with
measures of cardiovascular disease risk and markers of damage
due to MI. Remarkably, CD11c receptor number on Mon2 in-
creased steadily from low- to high-risk subjects as a function of
serum triglyceride level and was highest on patients with MI.
Microﬂuidic devices have proven to be effective tools for quan-
tifying the adhesion potential of leukocytes as they ﬂow across
endothelial monolayers or substrates presenting recombinant
adhesion molecules (22). Shearing blood over a recombinant
VCAM-1 substrate resulted in enrichment of Mon2 with an ef-
ﬁciency of capture that exceeded Mon1 and Mon3. Although
Mon3 had the highest baseline expression of CD11c relative to
other subsets, Mon2 exhibited a ∼sevenfold greater recruitment
to VCAM-1 under shear ﬂow that was dependent on high-afﬁnity
CD11c and VLA-4. Mon2 was the most responsive subset to
hypertriglyceridemia and MI injury as indicated by signiﬁcant
increases in CD11c expression and capacity to arrest on VCAM-
1. A positive linear regression emerged when comparing CD11c
expression and recruitment efﬁciency of Mon2, allowing distinc-
tion between low-risk, high-risk, and MI cohorts. These ﬁndings
suggest that CD11c expression and VLA-4 avidity for binding to
VCAM-1 on Mon2 could provide a subject-speciﬁc measure of
cardiovascular risk, although larger scale studies incorporating
other clinical characteristics will be necessary to conﬁrm the
clinical utility of such an approach.
CD11c and VLA-4 Cooperate During Recruitment of Mon2 on VCAM-1.
A shift in integrin conformation from low to high afﬁnity and
clustered distribution facilitates leukocyte arrest on inﬂamed
sites in the vasculature (23). Using our laboratory-chip device,
we observed that monocyte arrest was dependent on recognition
and binding of VLA-4 to VCAM-1 and this was modulated by
CD11c afﬁnity state. Importantly, the hierarchy in recruitment of
Mon2 for high-risk subjects and MI patients was accounted for
by increased surface expression and function of the activated
conformation of CD11c. The synergistic relationship between
CD11c activation and VLA-4 binding to VCAM-1 was depen-
dent on activation of PLC, a signaling molecule that mediates
Ca2+ ﬂux and redistribution and stabilization of focal clusters of
high-afﬁnity VLA-4 that support monocyte adhesion strength-
ening at arterial levels of shear stress (24). TIRF optics, which
excite only membrane receptors in contact with the substrate,
revealed that CD11c number increased fourfold on monocytes
from high-risk subjects and MI patients, and this correlated with
a 60% enrichment in VLA-4 bound to VCAM-1. Focal clustering
of VLA-4 is a mechanism associated with adhesion strengthening
of recruited monocytes under shear ﬂow (25) and is cooperative
with β2 integrin activation to a high-afﬁnity state. Monocyte arrest
on VCAM-1 in this laboratory-chip assay required VLA-4, as
indicated by abrogation of recruitment in the presence of func-
tion-blocking antibody. VCAM-1 can serve as a ligand for high-
afﬁnity CD11c, and we observed a threefold enrichment of
CD11c over VLA-4 redistributed within the contact region upon
activation in vitro with TGRL or detected in ex vivo blood sam-
ples in high-risk and in MI patients. We also found that stabilizing
CD11c at low afﬁnity with the allosteric antibody 496K abrogated
the increase in Mon2 arrest observed in high-risk and MI subjects.
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Fig. 6. CD11c and VLA-4 density and topography on monocytes at adhesive
contact with VCAM-1. (A) TIRF images of anti-CD11c and anti–VLA-4 reveal
receptors in contact with VCAM-1 acquired from postprandial study subjects;
low-risk (n = 4), high-risk (n = 5), and MI patients (n = 5) (images are repre-
sentative of 20–30 monocytes per subject). (Scale bar, 10 μm.) Receptor num-
ber was quantiﬁed using calibration beads as described in SI Materials and
Methods. (B) TIRF images of CD11c and VLA-4 on monocytes treated with al-
losteric antibody 496B-activation, 496K-inactivation, or an isotype control
antibody (images are representative of 20–30monocytes per condition). (Scale
bar, 10 μm.) Number of CD11c and VLA-4 receptors on arrested monocytes
from healthy donors (n = 5). Monocytes in blood were treated with 496B,
496K, or isotype control prior to the adhesion assay. (C) Integrin colocalization
on VCAM-1 was imaged by TIRF microscopy on monocytes incubated with
TGRL or control Intralipid, and a group was pretreated with the PLC inhibitor
U73122 (images are representative of 15–20 monocytes per condition). VLA-4
(red) coalescence with CD11c (green) or VLA-4 with CD45 at the contact site
was quantiﬁed using Pearson’s coefﬁcient. Signiﬁcance was determined by
one-way ANOVA with Tukey posttest.
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Thus, the molecular mechanisms underlying CD11c cooperation
with VLA-4 remain unknown, but may involve CD11c shift to
high afﬁnity in circulation, subsequent recognition of focally
expressed VCAM-1 on inﬂamed endothelium stabilization, and
localization of high-afﬁnity VLA-4 within lipid rafts that are
enriched in cytoplasmic paxillin, talin, and Src family kinases
(SFKs) (26). Current studies in our laboratory are focused on
quantifying the spatial and temporal dynamics of CD11c and
VLA-4 redistribution and their possible colocalization with
adapter proteins and SFKs during adhesion to VCAM-1 under
shear ﬂow.
Lab-on-a-Chip Assay for Assessing the Severity of CVD. In this study,
we report that CD11c and VLA-4 receptor expression on Mon2
and relative capacity to recruit on VCAM-1 in shear ﬂow provide
a sensitive readout of perturbations in the inﬂammatory and
metabolic status of an individual. CD11c and VLA-4 receptor
expression levels on Mon2 increased by ∼25% and ∼5%, re-
spectively, from fasting to the postprandial state, whereas re-
ceptor numbers of both integrins increased by 100% in patients
with MI. Mon2 recruitment on VCAM-1 proved to be the best
discriminator of activation, increasing by 60% from low- to high-
risk (P < 0.01) and 87% from low-risk to MI patients (P < 0.005).
Our portable and personalized laboratory-chip assay within
minutes provides a rapid measure of monocyte activation state
that can resolve differences between subjects with risk factors for
atherosclerosis or with established coronary disease such as acute
MI. In the case of early atherosclerosis, identiﬁcation of Mon2
activation may prompt a clinician to prescribe more intensive
lifestyle modiﬁcations that are speciﬁc to predisposing risk fac-
tors, such as dietary lipids or high blood pressure. Among patients
with MI, increased Mon2–CD11c activation may identify patients
at elevated risk for recurrent cardiovascular events. Speciﬁc
interventions to abrogate Mon2–CD11c activation could also
limit infarct size by limiting Mon2 localization during an acute
MI. Further longitudinal characterization of Mon2–CD11c levels
and their contribution to atherosclerosis could lead to de-
velopment of unique risk markers and therapeutics for patients
with cardiovascular disease.
Materials and Methods
Subjects. Twenty-six healthy subjects (10 female) were recruited for the meal
study, nine subjects (three female) were recruited for the fructose feeding
study, and an additional 18 fasting patients (four female) with acute MI were
recruited from the University of California Davis Medical Center. All ex-
periments were approved by institutional review board protocols at the
University of California, Davis. Participating subjects and patients provided
informed consent as approved by institutional review board protocols at the
University of California, Davis. Clinical characteristics for the recruited
cohorts are available in Tables S1–S4.
Antibodies. Commercially available antibodies are listed in SI Materials and
Methods. CD11c monoclonal antibodies 496K and 496B, which inactivate or
activate CD11c, respectively, were obtained from Eli Lilly.
Flow Cytometry. Whole blood was drawn via venipuncture and immediately
cooled to 4 °C. After labeling with ﬂuorescent antibodies for 30 min, red
blood cells were removed with lysis buffer (eBiosciences). LDV-FITC (Tocris
Bioscience) was used to label high-afﬁnity VLA-4 at 30 nM. Data were ac-
quired on a BD FACScan cytometer within 2 h of venipuncture. The gating
scheme for identiﬁcation of monocyte subsets is shown in Fig. S5.
Whole Blood Adhesion Assay. Design and assembly of the microﬂuidic device
and the whole blood adhesion assay are described in SI Materials and
Methods. Arrested monocytes were discriminated into subsets using quan-
titative immunoﬂuorescence (Fig. S6). Quantiﬁcation of receptor topogra-
phy is described in SI Materials and Methods.
Statistics. Data are reported as mean ± SEM. Multiple groups were com-
pared using one-way ANOVA with Tukey posttest. Multiple time points
were compared using a repeated measures one-way ANOVA with Dun-
nets posttest. All analyses were carried out using Graph Pad Prism version
5.0d for Mac.
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